Lee Frank D.'s most recent trade in Bausch Health Companies Inc was a trade of 54,347 Common Shares, No Par Value done . Disclosure was reported to the exchange on May 16, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bausch Health Companies Inc | Frank D. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 54,347 | 89,707 (0%) | 0% | 0 | Common Shares, No Par Value | |
| Pacira BioSciences Inc | Frank D. Lee | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 350,000 | 448,409 (1%) | 0% | 0 | Common Stock | |
| Pacira BioSciences Inc | Frank D. Lee | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.33 per share. | 02 Jan 2025 | 9,375 | 98,409 (0%) | 0% | 18.3 | 171,844 | Common Stock |
| Pacira BioSciences Inc | Frank D. Lee | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 12.10 per share. | 12 Aug 2024 | 8,264 | 107,784 (0%) | 0% | 12.1 | 99,994 | Common Stock |
| Bolt Biotherapeutics Inc | Frank D. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Bausch Health Companies Inc | Frank D. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 35,360 | 35,360 (0%) | 0% | 0 | Common Shares, No Par Value | |
| Pacira BioSciences Inc | Lee Frank D. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 692,512 | 692,512 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Lee Frank D. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 99,520 | 99,520 (0%) | 0% | 0 | Common Stock | |
| Bolt Biotherapeutics Inc | Frank D. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Bolt Biotherapeutics Inc | Frank D. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2022 | 22,140 | 22,140 | - | - | Stock Option (Right to Buy) | |
| Bolt Biotherapeutics Inc | Frank D. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2022 | 14,071 | 14,071 | - | - | Stock Option (Right to Buy) | |
| Bolt Biotherapeutics Inc | Frank D. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2021 | 27,860 | 27,860 | - | - | Stock Option (Right to Buy) |